U. S. Centers for Disease Control Approves Partnership Agreement With The Quigley Corporation
U. S. Centers for Disease Control Approves Partnership Agreement With The Quigley Corporation
(PRWEB) October 25, 2002
DOYLESTOWN, PA, The Quigley Corporation (NASDAQ: QGLY), today announced it has entered into a partnership agreement with Centers for Disease Control and Prevention (CDC), under which The Quigley Corporation will distribute CDC cold and flu educational materials with Cold-Eeze® samples to physicians and other healthcare providers for their patients.
The National Center for Infectious Diseases (NCID) and CDC launched The National Campaign for Appropriate Antibiotics Use in the Community to educate healthcare providers and the public about the appropriate use of antibiotic therapy and the potential harm of unnecessary use of antibiotics.
According to the CDC, “While antibiotics should be used to treat bacterial infections, they are not effective against viral infections like the common cold, most sore throats, and the flu. Overuse of antibiotics is jeopardizing the usefulness of essential drugs. Decreasing inappropriate antibiotic use is the best way to control resistance.”
The Partnership Agreement or Memoranda of Understanding states that the NCID/CDC will supply The Quigley Corporation with educational materials. Quigley will in turn educate physicians and other healthcare providers receiving Cold-EEZE samples with the educational materials and will provide information about how to obtain additional CDC materials. The healthcare professionals will distribute one CDC brochure along with one sample package of Cold-EEZE to patients with viral upper respiratory infections in lieu of prescribing antibiotics.
Because COLD-EEZE has been shown to reduce the duration of the common cold in two double-blind clinical studies, The Quigley Corporation will provide Cold-EEZE samples to physicians in an effort to educate consumers regarding appropriate treatments for viral upper respiratory infections like the common cold.
In March of this year, The Quigley Corporation announced preliminary results of a retrospective clinical study documenting a 92% reduction in the use of antibiotics by patients who used Cold-EEZE as a first line treatment for the common cold. The independent retrospective study was conducted over a three-year period and spanned more than 170,000 patient days with a student population ranging in age from 12 to 18 years. The study has been accepted for publication by the American Journal of Therapeutics in an upcoming edition.
Guy J. Quigley, chairman, president, and chief executive officer stated, “The Quigley Corporation is proud to join the effort by The National Campaign for Appropriate Antibiotics Use in the Community and healthcare professionals around the nation to educate consumers on safer, more effective alternatives to antibiotics to treat the common cold. While other alternatives to antibiotics may treat cold symptoms, Cold-EEZE has been shown to reduce the duration of the common cold.
About the CDC
The Centers for Disease Control and Prevention (CDC) is recognized as the lead federal agency for protecting the health and safety of people at home and abroad, providing credible information to enhance health decisions, and promoting health through strong partnerships. CDC serves as the national focus for developing and applying disease prevention and control, environmental health, and health promotion and education activities designed to improve the health of the people of the United States. CDC, located in Atlanta, Georgia, USA, is an agency of the Department of Health and Human Services. For more information about The National Campaign for Appropriate Antibiotics Use in the Community log on to http://www. cdc. gov/drugresistance/community/ (http://www. cdc. gov/drugresistance/community/)
About The Quigley Corporation
The Quigley Corporation (NASDAQ: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGG™) lozenges, gums and sugar free tablets. Cold-EEZE is the only (ZIGG™) lozenge proven in two double-blind studies to reduce the duration of the common cold by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (www. QuigleyPharma. com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, unÂcertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
###
Jerry Schranz
PR for ColdEEZE
E: jschranz@schwartz. com
